Niagen Bioscience Posts 30% Revenue Growth, Strengthens IP Portfolio
Event summary
- Niagen Bioscience reported a 30% year-over-year net sales increase to $129.4 million in 2025, with net income rising 103% to $17.4 million.
- Fourth-quarter net sales grew 16% to $33.8 million, driven by a 21% increase in Tru Niagen® sales.
- The company acquired the core nicotinamide riboside (NR) patent portfolio from Queen’s University Belfast, enhancing its IP control.
- Niagen Bioscience launched Tru Niagen® Beauty, expanding into the beauty and nutricosmetics category.
- The company ended 2025 with $64.8 million in cash and no outstanding borrowings.
The big picture
Niagen Bioscience’s strong financial performance in 2025, marked by a 30% revenue increase and a 103% net income rise, underscores its strategic focus on growth and IP control. The acquisition of the NR patent portfolio from Queen’s University Belfast and the launch of Tru Niagen® Beauty reflect the company’s efforts to strengthen its market position and expand into new verticals. The company’s robust cash position and absence of borrowings provide a solid foundation for continued investment in strategic priorities.
What we're watching
- IP Strategy
- The acquisition of the NR patent portfolio from Queen’s University Belfast will be critical to watch, as it enhances Niagen Bioscience’s control over key IP supporting existing and potential future applications.
- Product Expansion
- The launch of Tru Niagen® Beauty marks the company’s entry into the beauty and nutricosmetics category, which could drive further revenue growth if successfully executed.
- Financial Performance
- The company’s ability to sustain its strong financial performance, including a 30% revenue increase and a 103% net income rise, will be a key indicator of its long-term strategic success.
Related topics